Clinical trials: 2019-nCoV
Coronavirus, Corona Virus Infection
PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs
PHENOTYPE is an investigator-led, observational cohort study which aims to explore the long-term outcomes of patients with COVID-19 infection and to identify potential risk factors and biomarkers that can prognosticate disease…
- Conditions
- Coronavirus, Corona Virus Infection, COVID-19, 2019nCoV
- Trial name
- PHENOTYPE (NCT04459351)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
COVID-19, Corona Virus Infection
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV
- Trial name
- NCT04334967
- Testing
- Hydroxychloroquine, Vitamin C
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- CONTACT (NCT04611230)
- Where
- United States
- Volunteers
- 1,007 people
- Sponsor
- AbbVie
Laboratory Confirmed SARS-CoV-2 Infection Without Symptoms
Seroepidemiological Investigation of Coronavirus 2019 (COVID-19) Infection in Gabon
Gabon is the 3rd country most affected by COVID-19 behind Cameroon and Democratic Republic of Congo in Central Africa, with 8860 cases and 54 deaths in critically ill patients, since the first confirmed case of COVID-19 on the…
- Trial name
- Sero-CoV (NCT05065632)
- Testing
- Wantai kit Elisa
- Where
- Gabon
- Volunteers
- 3,455 people, healthy volunteers welcome
- Sponsor
- Prof. Ayola Akim ADEGNIKA
COVID-19, Coronavirus 2019
Genetics of COVID-19 Susceptibility and Manifestations
Background: Coronavirus 2019 (COVID-19, or SARS-CoV-2) is a serious public health problem, and genetics may play a role in how serious the illness becomes in certain people.
- Trial name
- NCT04371432
- Where
- United States
- Volunteers
- 721 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Coronavirus Infectious Disease 2019 (COVID-19)
COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)
This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleic acid analysis platform from, but not limited to, saliva to help enable and support contact tracing in the canton of Baselland/ Switzerland.
- Trial name
- NCT04625257
- Testing
- Saliva based assay: crude RNA extraction, Validation of the NGS method, Validation of the LAMP assays
- Where
- Switzerland
- Volunteers
- 1,600 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting.
- Trial name
- ROCOVI (NCT05196477)
- Testing
- Olokizumab, Standard therapy
- Where
- 6 sites in Russia
- Volunteers
- 3,087 people
- Sponsor
- R-Pharm
COVID-19
SCB-2019 as COVID-19 Vaccine
This is a randomized, double blind, placebo controlled, first-in-human (FIH) study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects.
- Trial name
- NCT04405908
- Testing
- SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
- Where
- Australia
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Acute Pancreatitis, 2019 Novel Coronavirus Infection
Study and Analysis of Acute Pancreatitis Complicated With COVID-19
The goal of this observational study was to explore the complex relationship between changes in the intestinal microbiome and serum metabolites in patients with novel coronavirus infection and acute pancreatitis.
- Trial name
- NCT05722678
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yuansong Sun
Coronavirus Infection, Critical Illness
Clinical Characteristics of Critically Ill Patients With COVID-19
Critically ill patients with COVID-19 have hospitalized in an ICU due to the closer monitoring and therapy. In fact, ICU admissions are dependent on the severity of illness and the ICU capacity of the health-care system.
- Conditions
- Coronavirus Infection, Critical Illness, Characteristics Disease
- Trial name
- NCT04413435
- Testing
- File Scanning
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people
- Sponsor
- Nevsehir Public Hospital
Post-COVID-19
Sleep Characteristics in Post-COVID-19 Patients
After acute infection, patients with coronavirus disease 2019 (COVID-19) often suffer from persisting symptoms for more than 3 months (post COVID-19).
- Trial name
- NCT05124548
- Testing
- Sleep diagnostics
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Coronavirus
Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations
Outbreak of 2019 Novel Coronavirus infection quickly spread to the world. Confirmed patients were isolated and treated in our department. 2019 Novel Coronavirus was detected in multiple organ system.
- Trial name
- NCT04279795
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Severe Acute Respiratory Syndrome Coronavirus 2
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.
- Trial name
- NCT04360486
- Testing
- Anti-Sars-CoV-2 Convalescent Plasma
- Where
- 38 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command
2019 Novel Coronavirus Infection
Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff
The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.
- Trial name
- NCT04320238
- Testing
- recombinant human interferon Alpha-1b, thymosin alpha 1
- Where
- China
- Volunteers
- 2,944 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Coronavirus Disease 2019
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04672564
- Testing
- Carrimycin
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 93 people
- Sponsor
- Shenyang Tonglian Group CO., Ltd
Covid19, SARS (Severe Acute Respiratory Syndrome)
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family.
- Trial name
- NCT04590274
- Testing
- Hydroxychloroquine, Vitamins and Minerals, Azithromycin
- Volunteers
- healthy volunteers welcome
- Sponsor
- International Brain Research Foundation
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Healthy Participants
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
- Trial name
- NCT07093580
- Testing
- S-892216-LAI
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Shionogi
Covid19
Risk Factors Worsening COVID19 for Out-patient With Home Monitoring
The main objective of the COVIDADOMEVA study is to identify the risk factors aggravating the COVID-19 (risk or protective factors), in out-patients suspected of being infected with precocious home monitoring.
- Trial name
- COVIDADOMEVA (NCT04380662)
- Testing
- Risk factors
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Grenoble
New Coronavirus
Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV
In late December 2019, several local health facilities reported clusters of patients with pneumonia of unknown cause that were epidemiologically linked to a seafood and wet animal wholesale market in Wuhan, Hubei Province, China.
- Trial name
- NCT04245631
- Testing
- Recombinase aided amplification (RAA) assay
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Ditan Hospital